Report cover image

Galderma SA (GALD) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Feb 16, 2026
Length 57 Pages
SKU # GBDT20881267

Description

Galderma SA (GALD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Galderma SA (Galderma) provides science-based solutions for skin health. The company’s activities involve the development and distribution of skincare products and medical solutions. Its product portfolio includes prescription drugs, consumer skincare products and aesthetic solutions. The company’s major brands include Azzalure, Restylane, Sculptra, Cetaphil, and Alastin. Galderma serves its products to a wide range of skin health needs, for the treatment of maintaining healthy skin and rejuvenating aging skin. It is distributed through a network of healthcare professionals and retailers, reaching consumers across various industries. The company has a global presence, operating in over 90 countries. Galderma is headquartered in Lausanne, Lake Geneva, Switzerland.

Galderma SA Key Recent Developments

Feb 02,2026: U.S. FDA Accepts Galderma's RelabotulinumtoxinA BLA Resubmission
Feb 02,2026: Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Jan 30,2026: Galderma Addresses Menopause-Related Skin Changes and Includes Menopausal Status in Clinical Trials
Jan 30,2026: Galderma Tackles Menopause-Related Skin Changes With Global Survey and Clinical Trial Inclusivity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

57 Pages
Section 1 - About the Company
Galderma SA - Key Facts
Galderma SA - Key Employees
Galderma SA - Key Employee Biographies
Galderma SA - Major Products and Services
Galderma SA - History
Galderma SA - Company Statement
Galderma SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Galderma SA - Business Description
Product Category: Dermatological Skincare
Financials
Product Category: Injection Aesthetics
Financials
Product Category: Therapeutic Dermatology
Financials
Geographical Segment: International
Performance
Geographical Segment: USA
Performance
R&D Overview
Galderma SA - Corporate Strategy
Galderma SA - SWOT Analysis
SWOT Analysis - Overview
Galderma SA - Strengths
Galderma SA - Weaknesses
Galderma SA - Opportunities
Galderma SA - Threats
Galderma SA - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Galderma SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Galderma SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 02, 2026: U.S. FDA Accepts Galderma's RelabotulinumtoxinA BLA Resubmission
Feb 02, 2026: Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Jan 30, 2026: Galderma Addresses Menopause-Related Skin Changes and Includes Menopausal Status in Clinical Trials
Jan 30, 2026: Galderma Tackles Menopause-Related Skin Changes With Global Survey and Clinical Trial Inclusivity
Jan 29, 2026: Galderma Unveils ‘Wake up to Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-on Natural Beauty
Jan 21, 2026: Galderma Update on Arbitration Terminating Neuromodulator R&D Partnership With Ipsen
Jan 14, 2026: TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
Dec 17, 2025: New Data Confirm Nemluvio (Nemolizumab) Rapidly Relieves Itch and Improves Sleep Within Two Days in Atopic Dermatitis and Prurigo Nodularis
Dec 05, 2025: Galderma Opens up New Chapter for Sculptra With MDR Certification and New Expanded Indication for Body
Dec 05, 2025: Galderma Expands Sculptra Indications After EU MDR Certification
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Galderma SA, Key Facts
Galderma SA, Key Employees
Galderma SA, Key Employee Biographies
Galderma SA, Major Products and Services
Galderma SA, History
Galderma SA, Subsidiaries
Galderma SA, Key Competitors
Galderma SA, Ratios based on current share price
Galderma SA, Annual Ratios
Galderma SA, Annual Ratios (Cont...1)
Galderma SA, Annual Ratios (Cont...2)
Galderma SA, Interim Ratios
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Galderma SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Galderma SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Galderma SA, Performance Chart (2021 - 2024)
Galderma SA, Ratio Charts
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.